Strategic action for overcoming drug resistance in malaria – 2018
There is a need to develop safe and effective drugs that can be used to progress the malaria elimination agenda, and with a particular emphasis on pregnant women, infants and children. Current treatment of malaria is highly dependent on artemisinin-based combination therapies (ACT), but emerging resistance has highlighted the need to develop a broader portfolio of antimalarial drugs, including new or repurposed non-ACT drugs for chemoprevention and treatment as well as long-acting products with transmission-blocking potential.
This Call for proposals aimed to support one large-scale strategic action (clinical research activities) as part of a bigger portfolio of clinical trials with the capacity to develop new and diverse antimalarial drugs against Plasmodium falciparum and/or Plasmodium vivax, including combination therapies that may be used for treatment or chemoprevention of malaria in sub-Saharan Africa.
Call identifier: RIA2018SD